VEGFB and cardiac hypertrophy: To gain further insight into the molecular signatures involved in AAV9-Vegfb driven cardiac hypertrophy, we performed snRNA sequencing on snap-frozen heart tissues obtained from three AAV9-control vs. three AAV9-Vegfb treated 20-month-old mice, 8 weeks after AAV9-injection (Figure 5A).